No profile data available.
Alumis Inc. (ALMS) is a healthcare company in the autoimmune treatment pharmaceuticals industry, based in South San Francisco, United States, with about 237 full-time employees.
It reported revenue of $24.05 million for fiscal year 2025, and net income of -$243.33 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $1.66 million, down 37.7% from a year before. Its market capitalization was $926.76 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.
Alumis reported $24.05 million in revenue for fiscal year 2025. In Q2 2026 revenue was $1.66 million.
$926.76 million as of October 9, 2026.
Listed companies of a similar size in the same industry (autoimmune treatment pharmaceuticals) include Viridian Therapeutics, Inc. (VRDN), Alvotech (ALVO), Zenas BioPharma, Inc. (ZBIO), Rigel Pharmaceuticals, Inc. (RIGL).